5 "Urinary Bladder" clinical trials found.
-
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab TAR-200 Alone or Cetrelimab Alone in Participants with High-Risk Non- Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy
The purpose of the study is to determine the efficacy and safety of TAR-200 in combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in participants ... -
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or ...
-
A Phase 2 Open-Label Multi-Center Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible fo
This study looks at two treatments (TAR-200 + IV cetrelimab versus IV cetrelimab alone) for a specific kind of bladder cancer (muscle-invasive bladder cancer unsuitable for ...
-
A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy
If you have been diagnosed with urothelial cancer that has progressed or returned, you may be qualified for this Phase 2 study. The main goal ... -
Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other se
The purpose of the trial is to study a drug called BI 907828 for the treatment of certain types of advanced or spreading tumors. These ...